Trillium Health Resources Pharmacy Prior Approval Request for



Triptans

	mber Information				
1.	Last Name:	2			
3.	Last Name: Trillium ID #:	4. Date of Birth:		5. Gender:	
	scriber Information				
1.	Prescriber Name:		2. NPI #:		
3.	Requestor Name (Nurse/Office Staff): _				
4.	Requestor Name (Nurse/Office Staff): Mailing Address:		City:	State:	Zip:
3.	Phone #:	Ext	Fax #:		
Dru	g Information				
1.	Drug Name:	2. Strength:	3. Qu	uantity Per 30 Days:	
	Length of Therapy (in Days): ☐ up to 30 Day				
Clin	ical Information				
	equest for Non-Preferred Drug:				
1.	Failed two preferred drug(s). List preferred drugs failed: a. Was the failure due to an allergic reaction? □ Yes □ No				
	b. Was the failure due to a drug-to-	-drug interaction? ☐ `	Yes □ No		
2	Please describe reaction:	do offect on the new cutti	failure Diagon provi	ida aliminal informatio	
2.	Previous episode of an unacceptable sign	de effect or therapeution	c fallure. Please prov	ide ciinicai informatio	on:
3.	· · · · · · · · · · · · · · · · · · ·	r unique member circu	ımstance as a contra	indication to preferre	ed drug(s).
	Please provide clinical information:				
4. 5.	Age specific indications. Please give me Unique clinical indication supported by F	ember age and explain	:	lease explain and pr	ovide a
5.	general reference:	DA approvar or peer i	eviewed literature. F	lease explain and pr	ovide a
6.	Unacceptable clinical risk associated wit	th therapeutic change.	Please explain:		
Re	equest for Exceeding Quantity Limit (Ex	cceeding 12 per 30 da	avs):		
7.					
8.	Does the member have more than 6 moderate or severe headache? ☐ Yes ☐ No				
9.	Does the member have a history of NSAID therapy in the past year? Yes No				
	Does the member have a contraindication or allergy to NSAID therapy? ☐ Yes ☐ No				
	Is the member currently receiving therapy with a migraine preventative? Yes No				
	. Does the member have a contraindication	, ,			ns?
	☐ Yes ☐ No Please list:	<u>-</u>			
13	. Did the member have no clinical benefit	after at least a 90 day	trial of preventative i	medications at the m	aximum
	tolerated dose? ☐ Yes ☐ No				
14	. Has the member been diagnosed with Is		•	r Disease, Cerebrov	ascular
	Disease, Ischemic Bowel Disease, or Hemiplegic Migraine? ☐ Yes ☐ No				
	Has the member received an MAO Inhibitor in the past 2 weeks? ☐ Yes ☐ No				
16	. Will the beneficiary have concurrent use of (or use within 24 hours) ergotamine-containing or ergot-type medication? ☐ Yes ☐ No				
17	. Will the beneficiary have concurrent use	of (or use within 24 h	ours) another 5- HT1	agonist? □ Yes □ I	No
	Does the member have uncontrolled hypertension or basilar migraine? Yes No				
	. Has the prescriber reviewed the DHB ev		•		?
	☐ Yes ☐ No				
	_				
c:	ignature of Prescriber:		D-+-		
- 51	SUSTINE OF SECTIONS.		Date	•	

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.